CD103+ tumor-resident CD8+ T cell numbers underlie improved patient survival in oropharyngeal squamous cell carcinoma.

Journal for Immunotherapy of Cancer
Rehana HewavisentiUmaimainthan Palendira

Abstract

Human Papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC) is one of the fastest growing cancers in the Western world. When compared to OPSCCs induced by smoking or alcohol, patients with HPV+ OPSCC, have better survival and the mechanisms remain unclear. The Cancer Genome Atlas (TCGA) database was examined for genes associated with tissue-resident CD8+ T cells. Multiplex immunohistochemistry (IHC) staining was performed on tumor specimen taken from 35 HPV+ and 27 HPV- OPSCC patients. TCGA database revealed that the expression of genes encoding CD103 and CD69 were significantly higher in HPV+ head and neck SCCs (HNSCC) than in HPV- HNSCC. Higher expression levels of these two genes were also associated with better overall survival. IHC staining showed that the proportion of CD103+ tumor-resident CD8+ T cells were significantly higher in HPV+ OPSCCs when compared to HPV- OPSCC. This higher level was also associated with both lower risk of loco-regional failure, and better overall survival. Importantly, patients with HPV- OPSCC who had comparable levels of CD103+ tumor-resident CD8+ T cells to those with HPV+ OPSCC demonstrated similar survival as those with HPV+OPSCC. Our results show that CD103+ tumor-r...Continue Reading

References

Nov 30, 2005·Nucleic Acids Research·Keith K Stanley, Elektra Szewczuk
Jan 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul M WeinbergerAmanda Psyrri
Jan 24, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cécile BadoualEric Tartour
Aug 8, 2007·International Journal of Cancer. Journal International Du Cancer·Serge J SmeetsRuud H Brakenhoff
May 27, 2010·International Journal of Cancer. Journal International Du Cancer·Angela M HongBarbara R Rose
Aug 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M HongB Rose
Nov 6, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John R WebbBrad H Nelson
Mar 1, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fayçal DjenidiFathia Mami-Chouaib
Mar 10, 2016·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Angela HongBarbara Rose
Jun 20, 2017·Nature Immunology·Anusha-Preethi GanesanChristian H Ottensmeier
Mar 31, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jarem EdwardsUmaimainthan Palendira
May 2, 2018·Cancer·Anil K Chaturvedi, Zachary S Zumsteg
Sep 22, 2018·Lancet·Gilliam PrueMark Lawler
May 17, 2019·Cancers of the Head & Neck·Cassie PanWendell G Yarbrough
Jul 1, 2019·Trends in Immunology·Simone L ParkLaura K Mackay
Sep 4, 2019·Nature Communications·Ainhoa ArinaRalph R Weichselbaum

❮ Previous
Next ❯

Citations

Jan 12, 2021·Frontiers in Oncology·Marij J P WeltersSjoerd H van der Burg

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
PCR
RNA-Seq

Software Mentioned

survminer
GraphPad
Prism
Tumor Immune Estimation Resource
Mantra Snap
survival
R
inForm
Mantra

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.